AirFit F30, ResMed’s First Minimal-Contact Full Face CPAP Mask, Now Available in the U.S., Canada
ResMed (NYSE: RMD, ASX: RMD) today announced the availability of its first minimal-contact full face CPAP mask, AirFit F30, the latest addition to its AirFit mask portfolio, which helps sleep apnea patients reduce facial marks, wear glasses in bed and curl up closer to their bed partner.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181015005185/en/
AirFit F30 full face CPAP mask: Side View (Photo: Business Wire)
Availability
AirFit F30 is available for sale now in the United States and Canada, and will be on display at the Medtrade Fall conference this week in Atlanta; visit ResMed’s Booth #2116.
AirFit F30 fits 93 percent of patients,1 and features a minimal-contact cushion that sits just below the nose, preventing top-of-the-nose red marks and irritation, plus reducing feelings of claustrophobia for some full face wearers. It also has ResMed’s QuietAir vent, making the mask quieter than ambient noise in the bedroom.
New claims: ResMed AirFit F30 vs. the competition
Nearly 2 to 1 patients preferred AirFit F30 over the current market leader in minimal-contact full face masks.2 When specifically asked about comfort, seal and ease of use, more patients picked AirFit F30 each time.2 AirFit F30 is also quieter than the current market leader, based on published performance (21 vs. 24 dBA),3 with fewer sleep disruptions reported due to airflow.2
“AirFit F30 is a clear choice over other minimal-contact full face masks,” said Jim Hollingshead, president of ResMed’s Sleep business. “We’re excited to now offer it, along with the rest of our full face, nasal and nasal pillows options, for an easy, comfortable, stable fit and a great night’s sleep.”
About ResMed
ResMed (NYSE: RMD, ASX: RMD), a world-leading connected health company with more than 6 million cloud-connected devices for daily remote patient monitoring, changes lives with every breath. Its award-winning devices and software solutions help treat and manage sleep apnea, chronic obstructive pulmonary disease and other respiratory conditions. Its 6,000-member team strives to improve patients’ quality of life, reduce the impact of chronic disease and save healthcare costs in more than 120 countries. ResMed.com
1 ResMed AirFit F30 fitting study of 75 patients conducted from April to
May 2018 in multiple U.S. locations.
2 ResMed AirFit F30 guided
clinical study of 23 patients conducted from June 8 to August 24 2018 in
Australia. Study tested ResMed AirFit F30 against Phillips Respironics
DreamWear full face (both masks are minimal-contact, full face).
3
ResMed AirFit user guide, 2018. Philips Respironics DreamWear full face
mask instructions for use, 2016.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181015005185/en/
Contact information
ResMed
For media:
Jayme Rubenstein
+1 858.836.6798
news@resmed.com
or
For
investors:
Amy Wakeham
+1 858.836.5000
investorrelations@resmed.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LambdaTest Launches Professional Services to Elevate Quality Engineering Excellence20.9.2024 18:00:00 EEST | Press release
LambdaTest, a leading cloud-based unified testing platform, officially introduced its Professional Services, designed to transform how organizations achieve quality engineering excellence. This service offers a comprehensive suite of end-to-end testing solutions, powered by AI-driven technology, ensuring maximum test coverage, optimized test scripts, and seamless framework migrations. The newly launched services address key challenges enterprises face today—enhancing testing efficiency, increasing coverage, and reducing bottlenecks in QA. LambdaTest Professional Services also offers tailored test suite development, ensuring that organizations can craft custom solutions suited to their specific needs, while ongoing efficiency maintenance ensures long-term performance and quality. With flexible pricing plans that scale as per business needs, LambdaTest’s Professional Services are built for agility, making it easier for businesses of any size to implement robust testing frameworks and sta
Alvaria’s Workforce Enterprise Suite Becomes Aspect20.9.2024 16:00:00 EEST | Press release
Alvaria, a pioneer in workforce management and contact center customer experience technology, servicing large global enterprises and rapidly growing consumer brands, announced the rebirth of Aspect in response to accelerated company growth and a demand for more complex tools to support hybrid, remote and in-person workforces. Aspect encapsulates Alvaria’s Enterprise Workforce Suite and will operate as an Alvaria-owned subsidiary. Aspect returns to the brand portfolio with a modern and innovative suite of products, including their new next-generation platform, WorkforceOS, powered by predictive analytics and a mission to humanize the service economy. Aspect has a rich history of innovation and leadership in the contact center space, having pioneered the world’s first Automatic Call Distribution (ACD) and the first Workforce Management Software for contact centers. Alvaria has named Darryl Kelly as Chief Executive Officer to steward this brand evolution. Kelly, an accomplished senior lea
Adtran’s Coherent 100ZR and FSP 3000 OLS to play key role in OIF’s ECOC open interoperability showcase20.9.2024 15:00:00 EEST | Press release
Adtran today announced its key role in the Optical Internetworking Forum’s (OIF) demonstration of open, multi-vendor networking at the European Conference on Optical Communication (ECOC) 2024. At the center of the showcase are Adtran’s Coherent 100ZR QSFP28 pluggable module and its FSP 3000 open optical line system (OLS), which enables the transport of a wide range of data rates, including 100ZR and 400Gbit/s OpenZR+, as featured in this demo. Incorporating 100Gbit/s to 800Gbit/s coherent pluggable transceivers and various OLS technologies from multiple vendors, the demo showcases advancements in open optical networking and innovative vendor-neutral solutions, highlighting the importance of testing multi-vendor interoperability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240920990844/en/ Adtran’s central role in the OIF demo underlines its commitment to developing open solutions that seamlessly interoperate with other ve
Matchday Champions , a New Class of Mobile Football Game Now Available Worldwide; Kicks off With In-Game Event Hosted by Soccer Superstar Alexia Putellas and Mega Influencer Celine Dept20.9.2024 14:00:00 EEST | Press release
Matchday, the developer of innovative mobile games for football’s five billion fans, has debuted its newest title, Matchday Champions. Today, the game is in early access globally, and it is celebrating with the limited-time “Copa Alexia x Céline,” a one-of-a-kind in-game tournament hosted by Spanish football World Cup Champion Alexia Putellas, and the immensely popular Belgian influencer Celine Dept. Backed by Lionel Messi’s Play Time fund, Alexia Putellas, and other industry legends in sports and games, Matchday Champions is a one-of-its-kind experience. The game allows players to collect, craft and manage their own dream squad made up of both men's and women's players. It delivers the excitement of football using a cutting edge narrative creation engine, ensuring no two matches are ever the same. More than two million people have already pre-registered ahead of launch. Matchday Champions is now available in early access globally for iOS and Android phones. Players who download the ga
Neu-REFIX Beta glucan receives rare pediatric disease and orphan drug designations from the US FDA for treatment of Duchenne Muscular Dystrophy20.9.2024 11:12:00 EEST | Press release
Neu REFIX Beta glucan, made in Japan has received both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (US FDA) for treatment of Duchenne muscular Dystrophy (DMD). These designations would help take the progress in pre-clinical and clinical studies conducted in Japan and India to clinical trials in the USA, for approval by FDA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240920153092/en/ The parable of the lost sheep mirrors our journey to find a solution for Duchenne Muscular Dystrophy (DMD), a rare disease. Our global interdisciplinary team is fortunate to have been gifted with Neu REFIX, whose hidden potentials of beneficial immune modulation, we unravelled by extensive preclinical and clinical studies. This gives hope to DMD patients for its potentials in improving their quality of life by halting the disease progress. Like the shepherd when he fou
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom